A case of metastatic lung adenocarcinoma of the bladder in a patient with no documented history of lung cancer

Azaiza, Mohammed; Yallapragada, Soumya; Siegert, James; Andros, Greg

doi:10.1016/j.eucr.2023.102441

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While metastases from SCLC to the bladder are described in the literature [ 18 ], several lines of evidence suggest that the present case is a primary SCBC with pulmonary metastasis. First, the genomic profile of the metastatic tumor is strongly in favor of a urothelial origin.…”

Section: Discussionmentioning

confidence: 81%

Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy

Moussa,

Khandelwal,

Wilson

et al. 2024

Current Oncology

View full text Add to dashboard Cite

Small cell bladder cancer (SCBC) is a rare and aggressive disease, often treated with platinum/etoposide-based chemotherapy. Key molecular drivers include the inactivation of onco-suppressor genes (TP53, RB1) and amplifications in proto-oncogenes (MYC). We report a patient with SCBC who achieved an objective and prolonged response to lurbinectedin, which has been approved for metastatic small cell lung cancer, after developing disease progression on cisplatin/etoposide and nivolumab/ipilimumab. A genomic analysis of a metastatic biopsy prior to lurbinectedin initiation revealed a TP53 mutation and amplification of the cell cycle regulators E2F3 and MYCL. A repeat biopsy following the development of lurbinectedin resistance showed a new actionable ERBB2 alteration without significant change in the tumor mutation burden (six mutations/Mb). The present report suggests that lurbinectedin may be active and should be further explored in SCBC harboring TP53 mutations and amplifications in E2F3 and MYC family complexes.

show abstract

Section: Discussionmentioning

confidence: 81%